Table 3.

Analyses for the use of lipid-lowering therapies and CV outcomes.

Treatment	Endpoint	Participant (lipid-lowering therapies/placebo)	RR	95% CI	P value	I2 (%)
Statins	MI	15,710/15,640	0.65	0.47–0.88	.005	67
	Stroke	12,261/12,264	0.76	0.42–1.39	.38	75
	CV death	12,870/12,413	0.81	0.56–1.17	.26	78
	Composite endpoint	15,132/15,134	0.92	0.63–1.34	.65	93
PCSK9-mAbs	MI	14,631/14,455	0.73	0.65–0.82	<.001	0
	Stroke	14,268/14,264	0.79	0.66–0.94	.01	0
	CV death	14,261/13,867	0.43	0.04–5.30	.51	64
Ezetimibe	MI	9474/9488	0.87	0.81–0.95	.001	0
	Stroke	9424/9440	0.86	0.74–1.00	.05	0
	CV death	9424/9440	1.00	0.89–1.12	.98	0

CI = confidence interval, CRP = C-reactive protein, CV = cardiovascular, MI = myocardial infarction, PCSK9-mAb = proprotein convertase subtilisin/kexin type 9 monoclonal antibody, RR = risk ratio.